Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer: LIBRA trial tests smart drug cocktails

NCT ID NCT07098338

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults will take part across 10 countries. The study is open to those with a specific protein marker (PD-L1 ≥1%) and who have not had prior treatment for advanced disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 278 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for All Sub-studies: * Participant must be ≥ 18 years of age at the time of signing the ICF * WHO/ECOG performance status of 0 or 1 * At least 1 lesion that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline. * Adequate bone marrow and organ function * Life expectancy ≥ 12 weeks * Provision of acceptable tumour tissue Specific Inclusion Criteria for Sub-Study 1 and Sub-Study 2: * Histologically or cytologically documented advanced or metastatic NSCLC * PD-L1 TC ≥ 1% (TC≥ 50% for sub-study 1, 1-49% for sub-study 2) * Absence of sensitizing EGFR mutations or ALK rearrangements. No known other Actionable Genomic Alterations(AGAs) Specific Inclusion Criteria for Sub-Study 3: * Histologically or cytologically documented advanced or metastatic non-squamous NSCLC * Documented positive AGA and had progressed on prior targeted therapy Exclusion Criteria for All Sub-studies: * As judged by the investigator, any severe or uncontrolled systemic diseases, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol * Active or prior documented autoimmune or inflammatory disorders * Persistent toxicities (CTCAE Grade ≥ 2) (NCI CTCAE v5.0) caused by previous anti cancer therapy, excluding alopecia. * Spinal cord compression or leptomeningeal carcinomatosis for sub-study 1 and sub-study 2. Unstable spinal cord compression for sub-study 3 * Unstable brain metastases * History of another primary malignancy. * Active infection, including TB and infections with HIV, HBV (verified by known positive HBsAg result), HCV. * Uncontrolled or significant cardiac disease * Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2. * Prior exposure to immune-mediated therapy * History of uncontrolled hypertension, and active bleeding diseases, and high risks of bleeding and disorders of coagulation * Any concurrent anti-cancer treatment. * Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    82 sites in 12 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Santa Monica, California, 90404, United States

  • Research Site

    NOT_YET_RECRUITING

    Santa Rosa, California, 95403, United States

  • Research Site

    RECRUITING

    Atlanta, Georgia, 30318, United States

  • Research Site

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21231, United States

  • Research Site

    NOT_YET_RECRUITING

    Houston, Texas, 77090, United States

  • Research Site

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Research Site

    NOT_YET_RECRUITING

    Heidelberg, 3084, Australia

  • Research Site

    NOT_YET_RECRUITING

    Nedlands, 6009, Australia

  • Research Site

    NOT_YET_RECRUITING

    Woodville, 5011, Australia

  • Research Site

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    RECRUITING

    Changsha, 410013, China

  • Research Site

    RECRUITING

    Chengdu, 610041, China

  • Research Site

    RECRUITING

    Deyang, 618000, China

  • Research Site

    RECRUITING

    Dongguan, 523059, China

  • Research Site

    WITHDRAWN

    Fuzhou, 350014, China

  • Research Site

    RECRUITING

    Guangzhou, 510080, China

  • Research Site

    RECRUITING

    Guangzhou, 510100, China

  • Research Site

    RECRUITING

    Hangzhou, 310014, China

  • Research Site

    RECRUITING

    Hefei, 230022, China

  • Research Site

    RECRUITING

    Linyi, 276001, China

  • Research Site

    RECRUITING

    Mianyang, 621000, China

  • Research Site

    RECRUITING

    Nanchang, 330000, China

  • Research Site

    RECRUITING

    Nanchang, 330006, China

  • Research Site

    RECRUITING

    Shantou, China

  • Research Site

    RECRUITING

    Shenyang, 110042, China

  • Research Site

    RECRUITING

    Wuhan, 430022, China

  • Research Site

    RECRUITING

    Zhengzhou, 450000, China

  • Research Site

    RECRUITING

    Zhengzhou, 450008, China

  • Research Site

    RECRUITING

    Zhuhai, 519000, China

  • Research Site

    NOT_YET_RECRUITING

    Avignon, 84902, France

  • Research Site

    NOT_YET_RECRUITING

    Paris, 75005, France

  • Research Site

    NOT_YET_RECRUITING

    Rennes, 35000, France

  • Research Site

    NOT_YET_RECRUITING

    Saint-Herblain, 44805, France

  • Research Site

    RECRUITING

    Suresnes, 92150, France

  • Research Site

    NOT_YET_RECRUITING

    Aviano, 33081, Italy

  • Research Site

    NOT_YET_RECRUITING

    Catania, 95123, Italy

  • Research Site

    NOT_YET_RECRUITING

    Meldola, 47014, Italy

  • Research Site

    NOT_YET_RECRUITING

    Milan, 20141, Italy

  • Research Site

    NOT_YET_RECRUITING

    Milan, 35128, Italy

  • Research Site

    NOT_YET_RECRUITING

    Orbassano, 10043, Italy

  • Research Site

    NOT_YET_RECRUITING

    Roma, 00144, Italy

  • Research Site

    NOT_YET_RECRUITING

    Rozzano, 20089, Italy

  • Research Site

    RECRUITING

    Bunkyō City, 113-8677, Japan

  • Research Site

    RECRUITING

    Fukuyama-shi, 722-0001, Japan

  • Research Site

    RECRUITING

    Kobe, 650-0047, Japan

  • Research Site

    RECRUITING

    Kurume-shi, 830-0011, Japan

  • Research Site

    RECRUITING

    Kyoto, 602-8566, Japan

  • Research Site

    RECRUITING

    Kyoto, 606-8507, Japan

  • Research Site

    RECRUITING

    Osaka, 541-8567, Japan

  • Research Site

    RECRUITING

    Sakaishi, 591-8555, Japan

  • Research Site

    RECRUITING

    Shinjuku-ku, 162-8655, Japan

  • Research Site

    RECRUITING

    Wakayama, 641-8510, Japan

  • Research Site

    RECRUITING

    Yokohama, 236-0051, Japan

  • Research Site

    RECRUITING

    Singapore, 119082, Singapore

  • Research Site

    RECRUITING

    Singapore, 168583, Singapore

  • Research Site

    RECRUITING

    Cheongju-si, 28644, South Korea

  • Research Site

    RECRUITING

    Namdong-gu, 21565, South Korea

  • Research Site

    RECRUITING

    Seongnam-si, 13496, South Korea

  • Research Site

    RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    RECRUITING

    Seoul, 06351, South Korea

  • Research Site

    RECRUITING

    Seoul, 3722, South Korea

  • Research Site

    RECRUITING

    Seoul, 5505, South Korea

  • Research Site

    RECRUITING

    Suwon, 16247, South Korea

  • Research Site

    RECRUITING

    Suwon, 16499, South Korea

  • Research Site

    NOT_YET_RECRUITING

    A Coruña, 15006, Spain

  • Research Site

    NOT_YET_RECRUITING

    Madrid, 28041, Spain

  • Research Site

    RECRUITING

    Manresa, 08243, Spain

  • Research Site

    RECRUITING

    Málaga, 29009, Spain

  • Research Site

    RECRUITING

    Santander, 39008, Spain

  • Research Site

    NOT_YET_RECRUITING

    Valencia, 46010, Spain

  • Research Site

    RECRUITING

    Liuying, 736, Taiwan

  • Research Site

    RECRUITING

    Taichung, 402, Taiwan

  • Research Site

    RECRUITING

    Taichung, 40447, Taiwan

  • Research Site

    RECRUITING

    Tainan, 70403, Taiwan

  • Research Site

    RECRUITING

    Tainan, 710, Taiwan

  • Research Site

    RECRUITING

    Taipei, 100, Taiwan

  • Research Site

    RECRUITING

    Taipei, 110, Taiwan

  • Research Site

    RECRUITING

    Taipei, 11217, Taiwan

  • Research Site

    RECRUITING

    Taoyuan, 00333, Taiwan

  • Research Site

    RECRUITING

    Bangkok, 10330, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Bangkok, 10400, Thailand

  • Research Site

    NOT_YET_RECRUITING

    Bangkok, 10700, Thailand

  • Research Site

    RECRUITING

    Banphaeo, 74120, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.